[Vismodegib in metastasized basal cell carcinoma]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Basal cell carcinoma (BCC) is typically curable but can become destructive and metastasize in rare cases.
• Metastatic or locally advanced BCC requires novel therapeutic strategies.
• Hedgehog pathway inhibitors, like vismodegib, represent a new class of drugs for BCC treatment.

Observation:

• A patient with metastasized basal cell carcinoma and basal cell nevus syndrome was treated within a clinical study.
• Vismodegib administration resulted in successful treatment of the patient's condition.
• Reported side effects included muscle cramps, dysgeusia, nausea, and alopecia.

Findings:

• Vismodegib demonstrated efficacy in treating a patient with metastatic basal cell carcinoma and basal cell nevus syndrome.
• The observed adverse events were manageable.
• This case highlights the potential of vismodegib in managing complex BCC cases.

Implications:

• Vismodegib is a viable therapeutic option for a select group of patients with advanced basal cell carcinoma.
• Further research into hedgehog pathway inhibitors is warranted for BCC management.
• This study contributes to understanding vismodegib's clinical application in rare BCC presentations.